Analysed ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) News Sources
Alnylam Pharmaceuticals (ALNY) Stock Looks Cheap After A 47% Fall Yet Rich On Earnings
25-08-2026
yahoo.com
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
28-08-2026
biopharmadive.com
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
28-08-2026
stocktwits.com
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
30-08-2026
yahoo.com
Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself
31-08-2026
yahoo.com
Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says
31-08-2026
yahoo.com
Hereditary Transthyretin Amyloidosis Market Insight, Epidemiology, and Market Forecast - 2036 Now Available Reveals Why a $3B Market Is Racing Toward a One-Time Curative Gene-Editing Therapy
04-09-2026
yahoo.com
What is the current price of ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ)?
The current price of ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) is $248.68.
ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) since the previous trading day is $1.17.
ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) since the previous trading day is 0.4727%.
What is the most recent average sentiment score for ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ)?
The most recent average sentiment score for ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ)?
The most recent sentiment for ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) is .
SEC-8K** Filing Available For ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.